Industry Insight: MedComms 18th April
In this week’s insights, we highlight topics such as Committee of Medical Journal Editors (ICMJE) recommendations, LATITUDES network provides tools for use in evidence synthesis, how would you respond to an inadvertent submission to a predatory journal, and The power of raw and honest storytelling in MedComms Updated International Committee of Medical Journal Editors (ICMJE) […]
Industry Insight: Healthcare 8 April
This week’s Healthcare Industry Insights focuses on changes to China’s medical-device industry, users’ experiences with health-related content on Youtube, and FDA approval for a new antibiotic. China’s medical device industry gets a makeover This Nature article (part of Nature Spotlight: Medical devices in China) highlights the intensified push by the Chinese Government to produce and […]
Industry Insights: AI 6 April
This artificial intelligence (AI) Industry Insight focuses on the latest updates on the use of AI in medical communications. We are covering topics such as how to support the transition to AI-powered healthcare, AI in medical publishing, and the launch of Scopus AI. How to support the transition to AI-powered healthcare This editorial from Nature […]
Industry Insight: MedComms 25th March
In this piece, we highlight topics in the medical publishing industry that we think are helpful for ongoing professional development. Is ChatGPT making scientists hyper-productive, journals fighting back against questionable images, and advancing clinical data transformation. Is ChatGPT making scientists hyper-productive? The highs and lows of using AI This article by Nature discusses the benefits […]
Industry Insight: Healthcare 15 March
Industry Insight: Healthcare 15 March This week our Healthcare Industry Insights focuses on a new approval indication for Novo Nordisk’s Wegovy, a pending decision on donanemab for Alzheimers, and potential withdrawal of the ALS drug, Relyvrio. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight Semaglutide […]
Industry Insights: AI 4 March
This artificial intelligence (AI) Industry Insight focuses on the latest updates on the use of AI in medical communications. We highlight Elsevier’s editorial policy on the use of generative AI in publication. We also take a look at two separate studies with one demonstrating how AI outperforms doctors in summarising health records and the other […]
Industry Insight: MedComms 28 February
In this piece, we highlight topics in the medical publishing industry that we think are helpful for ongoing professional development. All ongoing clinical trials in the European Union must transition to the Clinical Trials Information System by 31 January 2025 The European Medicines Agency has released a reminder that there is less than a year […]
Industry Insight: Healthcare 22 February
We have summarised three articles to help keep you informed of the latest developments in the industry. This week, our Healthcare Industry Insight looks at positive pre-clinical results for THIO, an investigational telomere targeting agent, in small-cell lung cancer. We also take a look at new FDA drug approvals for advanced melanoma and food allergens. […]
Industry Insights: AI 15 February
This artificial intelligence (AI) Industry Insight focuses on the latest updates on the use of AI in medical communications. We highlight a statement from the National Association of Science Writers on generative AI tools, an article that reviews the use of AI in writing scientific review articles, and, Niche Science & Technology’s Insider’s Insight on […]
Industry Insight: MedComms 10 February
In this piece, we highlight three topics in the medical publishing industry that are sparking discussions. We focus on the updated International Committee of Medical Journal Editors recommendations and the Accurate Consensus Reporting Document (ACCORD) reporting guidelines. We also take a look at an article on the state of pharmaceutical events and meetings in 2024. […]
Industry Insights: Healthcare 31 January
We have summarised three articles to help keep you informed of the latest developments in the industry. This week, our Industry Insights post looks at three important updates from the U.S. Food and Drug Administration (FDA). The FDA has investigated the risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T-cell […]
Industry Insights: AI 25 January
Industry Insights: AI 25 January
